600
Participants
Start Date
May 31, 2008
Primary Completion Date
June 30, 2009
Study Completion Date
June 30, 2009
ATI-5923
Dose Adjusted based on INR.
Coumadin (warfarin)
Dose adjusted based on INR.
Lankenau Institute for Medical Research, Wynnewood
York Clinical Research, Norfolk
Internal Medicine of Greer, Greer
Georgia Heart Specialists, Covington
Northeast Georgia Heart Center, PC, Gainesville
Jacksonville Heart Center - Pavillon, Jacksonville
Jacksonville Center for Clinical Research, Jacksonville
Jacksonville Heart Center - South, Jacksonville
St. Luke's Cardiology Associates, Jacksonville
Jacksonville Heart Center, Jacksonville Beach
Florida Research Network, LLC, Gainesville
Orlando Heart Center, Orlando
Nature Coast Clinical Research, Inverness
The Heart and Vascular Institute of Florida, Safety Harbor
Birmingham Heart Clinic, PC, Birmingham
The Heart Center, PC, Huntsville
Cardiology PC, Birmingham
Mobile Heart Specialists, PC, Mobile
Cardiovascular Research Institute, LLC, Canton
Community Clinical Research Center, Anderson
Endeavor Medical Research, PLC, Alpena
McFarland Clinic PC, Ames
Medical Associates Clinic, LLP, Pierre
DuPage Medical Group, Winfield
Fox Valley Clinical Research Center, LLC, Aurora
Illinois Heart and Lung Research Center, Normal
Heart and Vascular Clinic, Lacombe
Plaza Medical Group, PC, Oklahoma City
Cardiovascular Research Institute of Dallas, Dallas
New West Physicians Clinical Research, Golden
Southwest Heart, Tucson
Steljes Cardiology, PC, Henderson
Escondido Cardiology Associates, Escondido
Progressive Clinical Research, Vista
University of California San Diego Medical Center, San Diego
Bend Memorial Clinic, Bend
Daniel Gottlieb, MD, Burien
Cardiology Associates of Fairfield County, PC, Norwalk
Stamford Therapeutics Consortium, Stamford
Cardiology Associates of Fairfield County, PC, Trumbull
Androscoggin Cardiology Associates, Auburn
Lead Sponsor
ARYx Therapeutics
INDUSTRY